ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO765

Donor-Derived Cell-Free DNA (dd-cfDNA) for Assessment of Response After Treatment of Allograft Rejection

Session Information

Category: Transplantation

  • 2002 Transplantation: Clinical

Authors

  • Gohh, Reginald Y., Rhode Island Hospital, Providence, Rhode Island, United States
  • Akalin, Enver, Montefiore Medical Center, Bronx, New York, United States
  • Klein, Jeffrey A., University of Kansas Medical Center Department of Internal Medicine, Kansas City, Kansas, United States
  • Agrawal, Nikhil, CareDx Inc, Brisbane, California, United States
  • Shekhtman, Grigoriy, CareDx Inc, Brisbane, California, United States
  • Fu, Yi, CareDx Inc, Brisbane, California, United States
  • Weir, Matthew R., University of Maryland Baltimore, Baltimore, Maryland, United States
Background

Surveillance of dd-cfDNA after therapy for rejection represents a promising strategy for monitoring post-treatment response. We assessed post-rejection kinetics of dd-cfDNA among kidney transplant recipients in the Kidney allograft Outcomes AlloSure Registry (KOAR, NCT03326076).

Methods

We identified patients with biopsy-proven allograft rejection (BPAR), defined as ABMR, TCMR, or Mixed (Banff 2019), biopsy-paired dd-cfDNAmeasurements (within ≤30d of biopsy), and follow-up results 60-150 days after BPAR. When available, treatment and follow-up histology data was also analyzed.

Results

48 episodes of BPAR (24 TCMR, 19 ABMR, 5 Mixed) and paired dd-cfDNA results were identified in 42 patients. Overall, a significantreduction was seen between the median index (1.36%, IQR: 0.29-2.25) and follow-up dd-cfDNA results (0.35%, IQR: 0.13-0.95; p < 0.01) [Figure 1a]. For patients with concurrent eGFR measurements, no statistically significant improvement was seen. These patterns held when analysis was limited to TCMR and ABMR/Mixed rejections [Figure 1b, 1c]. 7 patients (2 ABMR, 4 TCMR, and 1 Mixed; median index dd-cfDNA 1.15%, IQR: 0.31-2.46) had repeat biopsies within 30days of their follow-up testing; 1 patient with acute ABMR had chronic active ABMR on repeat biopsy, with a dd-cfDNA of 1.86%, while the remainder had eitherno rejection or borderline findings (median dd-cfDNA 0.74%, IQR: 0.30-2.59).

Conclusion

Our findings highlight that reduction in dd-cfDNA is commonly seen following BPAR, suggesting that most patients experience a “molecularresponse” to therapy. Studies are needed to better understand the prognostic significance of a molecular response and how persistent elevations in dd-cfDNA after treatment should guide subsequent management.

Funding

  • Commercial Support